Exelixis (EXEL) Acquisitions (2010 - 2011)
Exelixis (EXEL) posted quarterly Acquisitions of $44000.0 for Q4 2011, down 89.0% year-over-year from $400000.0 in Q4 2010, and down 98.01% quarter-over-quarter from $2.2 million in Q3 2011.
Exelixis (EXEL) Acquisitions (2010 - 2011) Analysis & Trends
Exelixis' Acquisitions history runs 2 years deep, the most recent figure standing at $44000.0 for Q4 2011.
- In Q4 2011, Acquisitions fell 89.0% year-over-year to $44000.0; the TTM figure through Dec 2011 stood at $2.7 million (changed N/A YoY), while the FY2011 annual figure was $2.3 million, down 72.5% from the prior year.
- Acquisitions for Q4 2011 stood at $44000.0, down from $2.2 million in the prior quarter.
- The five-year high for Acquisitions was $3.3 million in Q2 2010, with the low at $44000.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 44,000.00 |
| Sep 30, 2011 | 2.21 Mn |
| Dec 31, 2010 | 400,000.00 |
| Jun 30, 2010 | 3.30 Mn |